{"entity":{"type":"insider","cik":"0001597583","url":"/insider/0001597583","json_url":"/insider/0001597583.json","name":"Browne L Daniel","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":19,"n_filings":15,"first":"2014-12-01","last":"2019-03-19","span_basis":"filed_date"},"name_variants":[{"name":"Browne L Daniel","source":"filing","n_filings":15,"first_seen":"2014-12-01","last_seen":"2019-03-19"}],"transactions":[{"id":8605605,"accession":"0001479290-19-000038","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001479290-19-000038","line_url":"/filing/0001479290-19-000038#line-3","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001597583","owner_name":"Browne L Daniel","owner_display_name":"Browne L Daniel","owner_url":"/insider/0001597583","role":"Director, Officer (CEO and President)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO and President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11613.0,"shares_display":"11,613","price_per_share":15.5057,"price_display":"15.51","price_state":"stated","total_value":180067.6941,"total_display":"180,067.69","total_whole":"180,068","shares_owned_after":151193.0,"shares_owned_after_display":"151,193","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-03-18","filed_date":"2019-03-19","scope":"insider"},{"id":8684812,"accession":"0001479290-19-000020","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001479290-19-000020","line_url":"/filing/0001479290-19-000020#line-2","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001597583","owner_name":"Browne L Daniel","owner_display_name":"Browne L Daniel","owner_url":"/insider/0001597583","role":"Director, Officer (CEO and President)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO and President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5446.0,"shares_display":"5,446","price_per_share":17.68,"price_display":"17.68","price_state":"stated","total_value":96285.28,"total_display":"96,285.28","total_whole":"96,285","shares_owned_after":168943.0,"shares_owned_after_display":"168,943","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-02-19","filed_date":"2019-02-20","scope":"insider"},{"id":5987511,"accession":"0001479290-18-000050","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001479290-18-000050","line_url":"/filing/0001479290-18-000050#line-4","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001597583","owner_name":"Browne L Daniel","owner_display_name":"Browne L Daniel","owner_url":"/insider/0001597583","role":"Director, Officer (CEO and President)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO and President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5452.0,"shares_display":"5,452","price_per_share":31.4284,"price_display":"31.43","price_state":"stated","total_value":171347.6368,"total_display":"171,347.64","total_whole":"171,348","shares_owned_after":141875.0,"shares_owned_after_display":"141,875","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-03-16","filed_date":"2018-03-16","scope":"insider"},{"id":5987504,"accession":"0001479290-18-000050","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001479290-18-000050","line_url":"/filing/0001479290-18-000050#line-2","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001597583","owner_name":"Browne L Daniel","owner_display_name":"Browne L Daniel","owner_url":"/insider/0001597583","role":"Director, Officer (CEO and President)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO and President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1000.0,"shares_display":"1,000","price_per_share":32.8,"price_display":"32.80","price_state":"stated","total_value":32800.0,"total_display":"32,800.00","total_whole":"32,800","shares_owned_after":130208.0,"shares_owned_after_display":"130,208","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-03-15","filed_date":"2018-03-16","scope":"insider"},{"id":6165482,"accession":"0001479290-18-000043","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001479290-18-000043","line_url":"/filing/0001479290-18-000043#line-1","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001597583","owner_name":"Browne L Daniel","owner_display_name":"Browne L Daniel","owner_url":"/insider/0001597583","role":"Director, Officer (CEO and President)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO and President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":27283.0,"shares_display":"27,283","price_per_share":31.43,"price_display":"31.43","price_state":"stated","total_value":857504.69,"total_display":"857,504.69","total_whole":"857,505","shares_owned_after":131208.0,"shares_owned_after_display":"131,208","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-03-07","filed_date":"2018-03-09","scope":"insider"},{"id":4543048,"accession":"0001209191-17-062450","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-17-062450","line_url":"/filing/0001209191-17-062450#line-1","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001597583","owner_name":"Browne L Daniel","owner_display_name":"Browne L Daniel","owner_url":"/insider/0001597583","role":"Director, Officer (CEO and President)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO and President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7600.0,"shares_display":"7,600","price_per_share":24.9434,"price_display":"24.94","price_state":"stated","total_value":189569.84,"total_display":"189,569.84","total_whole":"189,570","shares_owned_after":133188.0,"shares_owned_after_display":"133,188","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-11-22","filed_date":"2017-11-24","scope":"insider"},{"id":4268803,"accession":"0001209191-17-057690","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-17-057690","line_url":"/filing/0001209191-17-057690#line-1","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001597583","owner_name":"Browne L Daniel","owner_display_name":"Browne L Daniel","owner_url":"/insider/0001597583","role":"Director, Officer (CEO and President)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO and President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7662.0,"shares_display":"7,662","price_per_share":26.1557,"price_display":"26.16","price_state":"stated","total_value":200404.9734,"total_display":"200,404.97","total_whole":"200,405","shares_owned_after":140788.0,"shares_owned_after_display":"140,788","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-10-18","filed_date":"2017-10-20","scope":"insider"},{"id":4163860,"accession":"0001209191-17-053788","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-17-053788","line_url":"/filing/0001209191-17-053788#line-1","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001597583","owner_name":"Browne L Daniel","owner_display_name":"Browne L Daniel","owner_url":"/insider/0001597583","role":"Director, Officer (CEO and President)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO and President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7600.0,"shares_display":"7,600","price_per_share":23.577,"price_display":"23.58","price_state":"stated","total_value":179185.2,"total_display":"179,185.20","total_whole":"179,185","shares_owned_after":148450.0,"shares_owned_after_display":"148,450","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-09-20","filed_date":"2017-09-22","scope":"insider"},{"id":5037657,"accession":"0001209191-17-050347","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-17-050347","line_url":"/filing/0001209191-17-050347#line-2","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001597583","owner_name":"Browne L Daniel","owner_display_name":"Browne L Daniel","owner_url":"/insider/0001597583","role":"Director, Officer (CEO and President)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO and President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":22800.0,"shares_display":"22,800","price_per_share":22.7645,"price_display":"22.76","price_state":"stated","total_value":519030.6,"total_display":"519,030.60","total_whole":"519,031","shares_owned_after":156050.0,"shares_owned_after_display":"156,050","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-08-23","filed_date":"2017-08-25","scope":"insider"},{"id":5069170,"accession":"0001209191-17-035186","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-17-035186","line_url":"/filing/0001209191-17-035186#line-2","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001597583","owner_name":"Browne L Daniel","owner_display_name":"Browne L Daniel","owner_url":"/insider/0001597583","role":"Director, Officer (CEO and President)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO and President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":19713.0,"shares_display":"19,713","price_per_share":20.3465,"price_display":"20.35","price_state":"stated","total_value":401090.5545,"total_display":"401,090.55","total_whole":"401,091","shares_owned_after":164219.0,"shares_owned_after_display":"164,219","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-05-24","filed_date":"2017-05-24","scope":"insider"},{"id":5069163,"accession":"0001209191-17-035186","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-17-035186","line_url":"/filing/0001209191-17-035186#line-1","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001597583","owner_name":"Browne L Daniel","owner_display_name":"Browne L Daniel","owner_url":"/insider/0001597583","role":"Director, Officer (CEO and President)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO and President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12287.0,"shares_display":"12,287","price_per_share":20.1969,"price_display":"20.20","price_state":"stated","total_value":248159.3103,"total_display":"248,159.31","total_whole":"248,159","shares_owned_after":183932.0,"shares_owned_after_display":"183,932","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-05-22","filed_date":"2017-05-24","scope":"insider"},{"id":4539675,"accession":"0001209191-17-014560","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-17-014560","line_url":"/filing/0001209191-17-014560","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001597583","owner_name":"Browne L Daniel","owner_display_name":"Browne L Daniel","owner_url":"/insider/0001597583","role":"Director, Officer (CEO and President)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO and President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":11037.0,"shares_display":"11,037","price_per_share":20.571754253873337,"price_display":"20.57","price_state":"stated","total_value":227050.4517,"total_display":"227,050.45","total_whole":"227,050","shares_owned_after":200659.0,"shares_owned_after_display":"200,659","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-02-22","filed_date":"2017-02-24","scope":"insider","n_lines":2},{"id":4620847,"accession":"0001209191-17-006058","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-17-006058","line_url":"/filing/0001209191-17-006058#line-1","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001597583","owner_name":"Browne L Daniel","owner_display_name":"Browne L Daniel","owner_url":"/insider/0001597583","role":"Director, Officer (CEO and President)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO and President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12000.0,"shares_display":"12,000","price_per_share":19.7832,"price_display":"19.78","price_state":"stated","total_value":237398.4,"total_display":"237,398.40","total_whole":"237,398","shares_owned_after":184627.0,"shares_owned_after_display":"184,627","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-01-25","filed_date":"2017-01-27","scope":"insider"},{"id":3185713,"accession":"0001209191-16-157116","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-16-157116","line_url":"/filing/0001209191-16-157116#line-1","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001597583","owner_name":"Browne L Daniel","owner_display_name":"Browne L Daniel","owner_url":"/insider/0001597583","role":"Director, Officer (CEO and President)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO and President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12000.0,"shares_display":"12,000","price_per_share":20.9375,"price_display":"20.94","price_state":"stated","total_value":251250.0,"total_display":"251,250.00","total_whole":"251,250","shares_owned_after":195627.0,"shares_owned_after_display":"195,627","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-12-28","filed_date":"2016-12-30","scope":"insider"},{"id":3326634,"accession":"0001209191-16-152058","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-16-152058","line_url":"/filing/0001209191-16-152058","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001597583","owner_name":"Browne L Daniel","owner_display_name":"Browne L Daniel","owner_url":"/insider/0001597583","role":"Director, Officer (CEO and President)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO and President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12000.0,"shares_display":"12,000","price_per_share":17.91707425,"price_display":"17.92","price_state":"stated","total_value":215004.891,"total_display":"215,004.89","total_whole":"215,005","shares_owned_after":208449.0,"shares_owned_after_display":"208,449","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-11-25","filed_date":"2016-11-25","scope":"insider","n_lines":2},{"id":3298123,"accession":"0001209191-16-147362","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-16-147362","line_url":"/filing/0001209191-16-147362#line-1","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001597583","owner_name":"Browne L Daniel","owner_display_name":"Browne L Daniel","owner_url":"/insider/0001597583","role":"Director, Officer (CEO and President)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO and President","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12000.0,"shares_display":"12,000","price_per_share":14.8499,"price_display":"14.85","price_state":"stated","total_value":178198.8,"total_display":"178,198.80","total_whole":"178,199","shares_owned_after":219627.0,"shares_owned_after_display":"219,627","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-10-26","filed_date":"2016-10-28","scope":"insider"},{"id":7003451,"accession":"0001209191-14-072075","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-14-072075","line_url":"/filing/0001209191-14-072075#line-1","is_derivative":false,"issuer_cik":"0001479290","issuer_name":"Revance Therapeutics, Inc.","issuer_ticker":"RVNC","issuer_name_source":null,"issuer_url":"/issuer/0001479290","owner_cik":"0001597583","owner_name":"Browne L Daniel","owner_display_name":"Browne L Daniel","owner_url":"/insider/0001597583","role":"Director, Officer (CEO and President)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"CEO and President","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6000.0,"shares_display":"6,000","price_per_share":16.6699,"price_display":"16.67","price_state":"stated","total_value":100019.4,"total_display":"100,019.40","total_whole":"100,019","shares_owned_after":172626.0,"shares_owned_after_display":"172,626","ownership_form":"D","is_10b5_1":null,"transaction_date":"2014-11-28","filed_date":"2014-12-01","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":19,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":1,"open_market":true},{"code":"S","label":"Open-market sale","n":18,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":19},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001479290","name":"Revance Therapeutics, Inc.","url":"/issuer/0001479290","role":"Director, Officer (CEO and President)","n_filings":15,"first_seen":"2014-12-01","last_seen":"2019-03-19"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001597583","retrieved_at":"2026-08-23T06:17:12+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}